Meet PsyBio, A Company Producing Psilocybin From Genetically-Modified Bacteria
As psychedelics draw closer to legalization, companies in the industry have yet to figure out the most efficient and cost-effective way of producing psilocybin and other molecules on a commercial scale. To date, the industry has not reached a consensus as to the most effective production method to be used, once demand moves beyond clinical trials. PsyBio Therapeutics (TSXV:PSYB), a biotech company that uses genetically modified bacteria to biosynthesize psychedelic molecules, might have the answer to one of the industry’s most overlooked conundrums. Making Psilocybin From Bacteria PsyBio is...
Source: benzinga.com